[1]ÖÜ¿¡Ã÷,ºÎ¿×Íú,ÄßÑÞÐã,µÈ.ÌúÀë×ÓÏÞÖÆÏÂÖíÐØĤ·ÎÑ×·ÅÏ߸˾úÍâĤÄÒÅݵÄÖƱ¸¼°Æ俹ԭÐÔ·ÖÎö[J].½­ËÕũҵѧ±¨,2017,(01):119-123.[doi:10.3969/j.issn.1000-4440.2017.01.019 ]
¡¡ZHOU Jun-ming,HE Kong-wang,NI Yan-xiu,et al.Preparation of out membrane vesicles released by ª«Actinobacillus pleuropneumoniaeª« grown under iron-restricted conditions and evaluation of their antigenicity in a murine model[J].,2017,(01):119-123.[doi:10.3969/j.issn.1000-4440.2017.01.019 ]

µã»÷¸´ÖÆ

ÌúÀë×ÓÏÞÖÆÏÂÖíÐØĤ·ÎÑ×·ÅÏ߸˾úÍâĤÄÒÅݵÄÖƱ¸¼°Æ俹ԭÐÔ·ÖÎö()

·ÖÏíµ½£º

²Î¿¼ÎÄÏ×/References:

[1]SEBUNYA T N, SAUNDERS J R. Haemophilus pleuropneumoniae infection in swine: a review [J]. J Am Vet Med Assoc, 1983, 182: 1331-1337.ª¤
[2]PILETTE C, OUADRHIRI Y, GODDING V,et al. Lung mucosal immunity: immunoglobulin-A revisited [J]. European Respiratory Journal, 2001, 18: 571-588.ª¤
[3]WOOF J M, KERR M A. The function of immunoglobulin A in immunity [J]. Journal of Pathology, 2006, 208: 270-282.ª¤
[4]JOLIE R A V, MULKS M H, THACKER B J. Cross-protection experiments in pigs vaccinated with actinobacillus-pleuropneumoniae subtypes 1a and 1b [J]. Vet Microbiol, 1995, 45: 383-391.ª¤
[5]FURESZ S E, MALLARD B A, BOSSE J T, et al. Antibody- and cell-mediated immune responses of ª«Actinobacillus pleuropneumoniaeª«-infected and bacterin-vaccinated pigs [J]. Infect Immun, 1997, 65: 358-365.ª¤
[6]VAN DEN BOSCH H, FREY J. Interference of outer membrane protein PalA with protective immunity against ª«Actinobacillus pleuropneumoniaeª« infections in vaccinated pigs [J]. Vaccine, 2003, 21: 3601-3607.ª¤
[7]HENSEL A, STOCKHOFEZURWIEDEN N, PETZOLDT K, et al. Oral Immunization of pigs with viable or inactivated ª«Actinobacillus pleuropneumoniaeª« serotype-9 induces pulmonary and systemic antibodies and protects against homologous aerosol challenge [J]. Infect Immun, 1995, 63: 3048-3053.ª¤
[8]FENWICK B, HENRY S. Porcine pleuropneumonia [J]. J Am Vet Med Assoc, 1994, 204: 1334-1340.ª¤
[9]O¡äHAGAN D T, VALIANTE N M. Recent advances in the discovery and delivery of vaccine adjuvants [J]. Nature Reviews Drug Discovery, 2003, 2: 727-735.ª¤
[10]KOSER M L, MCGETTIGAN J P, TAN G S, et al. Rabies virus nucleoprotein as a carrier for foreign antigens [J]. Proc Natl Acad Sci USA, 2004, 101: 9405-9410.
[11]SINGH M, CHAKRAPANI A, O¡äHAGON D. Nanoparticles and microparticles as vaccine-delivery systems [J]. Expert Review of Vaccines, 2007, 6: 797-808.ª¤
[12]GUY B. The perfect mix: recent progress in adjuvant research [J]. Nature Reviews Microbiology, 2007, 5: 505-517.ª¤
[13]JABBAL-GILL I, LIN W, KISTNER O,et al. Polymeric lamellar substrate particles for intranasal vaccination [J]. Advanced Drug Delivery Reviews, 2001, 51: 97-111.ª¤
[14]CHABALGOITY J A. Paving the way for the introduction of new vaccines into developing countries [J]. Expert Review of Vaccines, 2005, 4: 147-150.ª¤
[15]ELLIS T N, KUEHN M J. Virulence and immunomodulatory roles of bacterial outer membrane vesicles [J]. Microbiology and Molecular Biology Reviews, 2010, 74: 81-94.ª¤
[16]VAN DER POL L, STORK M, VAN DER LEY P. Outer membrane vesicles as platform vaccine technology [J]. Biotechnology Journal, 2015, 10: 1689-1706.ª¤
[17]O¡äRYAN M, STODDARD J, TONEATTO D, et al. A multicomponent meningococcal serogroup B vaccine (4CMenB): The clinical development program [J]. Drugs, 2014, 74: 15-30.ª¤
[18]GERLACH G F, ANDERSON C, POTTER A A, et al. Cloning and expression of a transferrin-binding protein from ª«Actinobacillus pleuropneumoniaeª« [J]. Infection and Immunity, 1992, 60: 892-898.ª¤
[19]BAUMGARTEN T, SPERLING S, SEIFERT J, et al. Membrane vesicle formation as a multiple-stress response mechanism enhances pseudomonas putida DOT-T1E Cell surface hydrophobicity and biofilm formation[J]. Applied and Environmental Microbiology, 2012, 17: 6217-6224.ª¤ [20]BUETTNER F F R, KONZE S A, MAAS A, et al. Proteomic and immunoproteomic characterization of a DIVA subunit vaccine against ª«Actinobacillus pleuropneumoniaeª« [J]. Proteome Science, 2011, 9: 23.ª¤
[21]NEGRETE-ABASCAL E, GARCIA R M, REYES M E, et al. Membrane vesicles released by ª«Actinobacillus pleuropneumoniaeª« contain proteases and Apx toxins [J]. FEMS Microbiology Letters, 2000, 191: 109-113.ª¤
[22]GOTHE R, GONZ¦€LES O F, LINDNER T, et al. A novel strategy for protective ª«Actinobacillus pleuropneumoniaeª« subunit vaccines: detergent extraction of cultures induced by iron restriction [J]. Vaccine, 2001, 19: 966-975.
[23]BACHMANN M F, JENNINGS G T. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns [J]. Nature Reviews Immunology, 2010, 10: 787-796.
[24]ACEVEDO R, CALLIC¦V A, ARANGUREN Y, et al. Immune adjuvant effect of V. cholerae O1 derived proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi [J]. BMC Immunology, 2013, 14: 10.ª¤
[25]MURALINATH M, KUEHN M J, ROLAND K L, et al. Immunization with ª«Salmonella entericaª« serovar typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with ª«Streptococcus pneumoniaeª« [J]. Infection and Immunity, 2011, 79: 887-894.